A new therapeutic approach that can prevent the transformation of chronic intestinal inflammation in cancer

Researchers have succeeded in discovering a new therapeutic approach that can limit chronic bowel infections, and its development can occur in cancer, as this disease is one of the most complicated medical conditions in treatment, and associated with serious complications, such as the possibility of Crohn’s disease, or ulcerative colitis. The age group between 15 and 29 years is the most vulnerable to these diseases, especially if it coincides with genetic readiness and other factors. In a recent study, published in “Nature Immunology” magazine, researchers at Charity University Hospital in Berlin announced the discovery of a new therapeutic approach that could limit continuous intestinal inflammatory processes, which pave the way for more effective treatments in the future. The risk of cancer begins with diseases such as Crohn’s disease and ulcerative colitis, or in the form of severe episodes, coupled with severe abdominal cramps, diarrhea, weight loss, fatigue, in addition to increasing psychological pressure. Chronic intestinal inflammation can lead to permanent tissue damage and an increased risk of cancer. While traditional treatments focus on the entire immune system, modern treatments target specific molecules that are responsible for stimulating inflammation. The exact reasons behind such diseases are still fully understood to this day. In addition to genetic factors, it is also complicated that environmental effects play an important role in its development. Chronic intestinal inflammatory patients suffer from higher mortality rates (17 versus 12 per 1,000 people annually) compared to non -injured, with greater middle aged differences (between 20 and 59 years), and the average age of their expected age is 8 years less for women and 6 years for men. Understanding factors that predict early deaths can help improve health systems, and to target preventative efforts to most risk groups. A new therapeutic approach that the research team has succeeded in determining an interaction between two immune molecules: “Intercin-22” (IL-22), which is a multifunctional protein that plays an important role in maintaining tissue balance and protection against infection, in addition to “expenses” that plays a role in the recovery of tissue cells. But the surprise was that this interaction between IL-22 and Oncostatin m does not stop the inflammation, but rather exacerbates it as it is an interaction that feeds the inflammation. “We see that young people in the first place of their professional life, their conditions often do not respond to the available treatments. That’s why we urgently need new therapeutic methods,” said study researcher, Ahmed Hegazy, Professor of Digestion and Immunology in Shareite University Hospital. Hegazy added: “Our results provide a strong scientific basis for developing treatments directed against the mechanism to increase inflammation in patients with chronic inflammation of the gut, especially those suffering from severe forms of diseases.” Studies have shown that patients who have high levels of expostatin M do not respond to general treatments, which is an important indication of the severity of the disease and the possibility of treatment failure. Using advanced techniques, such as ‘single-cell sequence’, researchers have discovered that inflamed tissues contain a large number of cells that have receptors for expostatin m, compared to healthy tissues. The IL-22, which usually protects the tissues, increases the sensitivity of the tissue for this molecule by increasing the number of receptors, exacerbating inflammation. A new pile for patients in samples of patients with colon and rectal cancer caused by chronic inflammation of the intestines, the receptors of the on-costatin m were found extensively around the crops, but it was rare in the adjacent healthy tissues, which suggests that this inflammatory path can play a role in the development of cancer. However, chronic intestinal inflammation does not always lead to intestinal cancer, and not every patient is affected in the same way. The researcher who participated in the study told her side, Preta Zigmund, director of the Digestive Diseases Division at Charity University Hospital, that “the diseases of the intestinal inflammation are very complicated and differ from one of the other, and it makes its treatment difficult.” She added: “Thanks to our understanding of Oncostatin M with IL-22, we have a more clear vision of the reasons that lead to chronic bowel inflammation in some patients, which open the door to develop and test a new therapeutic approach.” The experimental results of the research team will soon be translated into a treatment, as an “antibody” test is currently being tested in a clinical trial, which aims to block the receptors of the Oncostatin M, which can help reduce chronic bowel inflammation and prevent the development of the disease in cancer.